天津医药

• 论著 •    

普罗布考联合辛伐他汀对急性冠脉综合征患者内皮功能的影响

张寰1,刘勇1,李焕明2,李永辉1   

  1. 1. 天津市第四中心医院
    2. 天津市第四中心医院心血管内科
  • 收稿日期:2010-01-27 修回日期:2010-03-17 出版日期:2010-05-15 发布日期:2010-05-15
  • 通讯作者: 张寰

Effects of Probucol combined with Simvastatin on Endothelial Function in Patients with Acute Coronary Syndrome

  • Received:2010-01-27 Revised:2010-03-17 Published:2010-05-15 Online:2010-05-15

PDF (PC)

1981

摘要： 目的：探讨普罗布考和辛伐他汀早期联合应用对急性冠状动脉综合征（ACS）内皮功能的影响。方法：将ACS患者随机分为单服辛伐他汀组（A组）以及辛伐他汀联合普罗布考组（B组），观察外周血氧化低密度脂蛋白（ox-LDL）和一氧化氮（NO）水平，应用高频超声检测肱动脉内皮依赖血管舒张功能（FMD），用药治疗3个月，比较治疗前后上述指标的变化。结果: 2组治疗前后ox-LDL下降的幅度，A组（125.0±22.3）mg/L低于B组（201.5±22.3）mg/L，有统计学意义（t=30.681,P<0.001）。2组治疗后NO升高的幅度， A组（7.22±2.85）umol/L 低于B组（0.81±3.21）umol/L，有统计学意义（t=17.3403,P<0.001）。2组治疗前后 FMD的差值比较，均有统计学意义（P<0.05）。结论：辛伐他汀合用抗氧化治疗能进一步改善ACS患者的内皮功能。

关键词: 急性冠脉综合征, 内皮, 降血脂药, 普罗布考

Abstract: Objective: The study investigate probucol combined with simvastation endothelial function in patients with acute coronary syndrome(ACS). Method :A total of 60 ACS patients randomly received standard therapy plus simvastatin (A,n=30) or standard therapy plus probucol combined with simvastatin (B,n=30). Plasma oxidized low-density lipoprotein(ox-LDL) and nitric oxide(NO) were measured.The brachial arterial hyperemia-induced flow mediated dilation(FMD) mediated vasodilatations were measured by high resolution ultrasound. These variables were analyzed before and after 3 months. Results: the difference of Plasma ox-LDL before and after the treatment between the two groups were lower in A group than in B group, had statistically significant(t=30.681,P<0.001). the difference of Plasma NO before and after the treatment between the two groups were rised in A group than in B group ， had statistically significant(t=17.3403,P<0.001).the difference of FMD before and after the treatment between the two groups were rised in A group than in B group ， had statistically significant(P<0.001).Conclusion: Simvastatin combined with ntioxidant probucol therapy could improve endothelial function in patients with acute coronary syndrome.

Key words: acute coronary syndrome, endothelium antilipemic agents probucol